BOSTON — AdvanCell Pty Ltd, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, has appointed Philina Lee, Ph.D., as Chief Executive Officer and member of the Board of Directors. Dr. Lee will lead the company’s U.S. expansion, accelerating clinical, manufacturing, and partnership efforts to advance its lead candidate, 212Pb-ADVC001, and its broader radiopharmaceutical pipeline. She will begin her role on January 1, 2026, and will be based at AdvanCell’s new U.S. headquarters near Boston and Cambridge, Massachusetts.
“Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb-ADVC001 and its emerging pipeline of targeted alpha therapies in the world’s largest pharmaceutical market.”
Dr. Lee previously served as Chief Commercial Officer at Blueprint Medicines Corporation, which was recently acquired by Sanofi for approximately US$9.5 billion. At Blueprint, she led commercial strategy and infrastructure development in oncology and mast cell disorders. She has also served on the Board of Directors of Fusion Pharmaceuticals Inc. and held senior roles at Algeta ASA, where she contributed to the U.S. launch of Xofigo (radium-223 dichloride), the first approved alpha therapy, in collaboration with Bayer AG.
Dr. Lee holds a B.S. in Biochemistry from the University of Alberta and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.
“AdvanCell is pioneering a new class of targeted alpha therapies powered by 212Pb (Lead-212) with tremendous potential to transform cancer treatment and position the company as the leading targeted alpha radiotherapy company,” said Dr. Philina Lee. “The clinical data from the Phase 1b part of the TheraPb trial recently presented for 212Pb-ADVC001 in prostate cancer at ESMO are promising, demonstrating an encouraging safety profile and strong therapeutic index, including a 100 percent overall rate of response in patients with RECIST-measurable lesions. I am excited to accelerate the expansion of our U.S. leadership and operational capabilities, building on AdvanCell’s strong foundation in Australia and advancing our mission to transform care for cancer patients globally.”
Dr. Lee succeeds founder and long-time CEO Andrew Adamovich, who will continue as Managing Director, Australia, and remain on the Board of Directors. Mr. Adamovich is credited with growing AdvanCell from concept to a leading clinical-stage, vertically integrated radiopharmaceutical company with manufacturing in Australia, a growing U.S. presence, and key partnerships across isotope supply, R&D, and clinical development.
“AdvanCell’s growth trajectory is remarkable—driven by our team’s relentless focus on improving outcomes for cancer patients based on innovative science and strong execution,” said Andrew Adamovich. “Philina’s leadership further strengthens our ability to establish the United States as a global hub while continuing to deliver innovation from Australia and cementing our position as a leader in targeted alpha radiotherapies.”
